â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

More documents

Recommendations

Info

ACCOUNTSCHIEF FINANCIAL OFFICER`s REPORTCash flowDuring 2000 operating activities resulted in a positive cash flow of DKK 504 million.This amount included a onetime payment of DKK 145 million from a partnercompensating royalty payments for the years 2001 – 2005. Working capitalincreased by DKK 35 million due to the increase in net turnover.Total cash proceeds from the divestiture of the Diagnostics division were DKK229 million, which were partly used for extraordinary repayments of DKK 44 millionon loans, compared to the original repayment scheme.Investments in fixed assets were DKK 139 million of which DKK 46 million relatedto distribution agreements concerning products such as Kestine ® .New capital amounting to DKK 31 million was issued during 2000 to finance theoperation of the new German subsidiary.The total positive cash flow generated in 2000 was DKK 443 million.Expectations to result for year 2001For the year 2001, continued growth in sales of the Groups key products isexpected to continue. This and the ongoing rationalisation of the product portfolioand production structure, are expected to yield double digit growth in the operatingresult and consequently a positive net result for the year.Profit distributionThe negative result of the year of DKK 43 million is proposed to be offset againstthe share premium account included in shareholder's equity.–38–
MANAGEMENT ENDORSEMENTRoskilde 15 th February 2001Board of managementHåkan BjörklundCEORunar BjørklundCFOBoard of DirectorsToni Weitzberg Robert Andreen Lars IngelmarkChairmanFredrik Strømholm Michael A Stevens Bo SøderbergConny DitlevsenJorunn Gaarder–39–
Page 2: CONTENT ANNUAL REPORT3 This is Nyco
Page 6 and 7: KEY FIGURESDKK million 2000 1999 *)
Page 8 and 9: CHAIRMAN`s REPORTThe Board is very
Page 10 and 11: CHIEF EXECUTIVE OFFICER´s REPORTA
Page 12 and 13: CHIEF EXECUTIVE OFFICER´s REPORTfr
Page 14 and 15: BOARD OF DIRECTORS1092865131171241
Page 16 and 17: MANAGEMENTThe management group in N
Page 18 and 19: BUSINESS DESCRIPTIONNYCOMED MARKETS
Page 26 and 27: BUSINESS DESCRIPTIONMAIN PRODUCTSC
Page 28 and 29: BUSINESS DESCRIPTIONMAIN PRODUCTSTa
Page 30 and 31: BUSINESS DESCRIPTIONMAIN PRODUCTSNy
Page 32 and 33: BUSINESS DESCRIPTIONPRODUCT ORIGINA
Page 34 and 35: BUSINESS DESCRIPTIONPRODUCT ORIGINA
Page 36 and 37: BUSINESS DESCRIPTIONQUALITY ASSURAN
Page 38 and 39: ACCOUNTSCHIEF FINANCIAL OFFICER`s R
Page 42 and 43: ACCOUNTSAUDITOR`s REPORT-40-
Page 44 and 45: ACCOUNTSACCOUNTING PRINCIPLESThe re
Page 46 and 47: ACCOUNTSACCOUNTING PRINCIPLESReceiv
Page 48 and 49: ACCOUNTSCONSOLIDATED BALANCE SHEETN
Page 50 and 51: ACCOUNTSCONSOLIDATED ACCOUNTS NOTES
Page 56 and 57: ACCOUNTSPARENT COMPANY PROFIT AND L
Page 58 and 59: ACCOUNTSPARENT COMPANY BALANCE SHEE
Page 60 and 61: ACCOUNTSPARENT COMPANY ACCOUNTS NOT
Page 62 and 63: ACCOUNTSPARENT COMPANY ACCOUNTS NOT
Page 64 and 65: ACCOUNTSOVERVIEW OF SUBSIDIARIESPar
Page 66 and 67: NYCOMED GROUP STRUCTURELEGAL STRUCT
Page 68 and 69: GermanyNycomed Pharma GmbHFraunhofe

â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

â rsrapport Nycomed - Takeda Pharmaceuticals International GmbH